Genomics & Informatics

Korea Genome Organization (한국유전체학회)
권호 표지
DOI QR코드

DOI QR Code

Chromothripsis in Treatment Resistance in Multiple Myeloma

  • Lee, Kyoung Joo (Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy) ;
  • Lee, Ki Hong (Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy) ;
  • Yoon, Kyong-Ah (College of Veterinary Medicine, Konkuk University) ;
  • Sohn, Ji Yeon (Department of Laboratory Medicine, Center for Diagnostic Oncology, Research Institute and Hospital, National Cancer Center) ;
  • Lee, Eunyoung (Center for Hematologic Malignancy, National Cancer Center) ;
  • Lee, Hyewon (Center for Hematologic Malignancy, National Cancer Center) ;
  • Eom, Hyeon-Seok (Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy) ;
  • Kong, Sun-Young (Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy)
  • Received : 2017.08.01
  • Accepted : 2017.08.29
  • Published : 2017.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Multiple myeloma (MM) is a malignant disease caused by an abnormal proliferation of plasma cells, of which the prognostic factors include chromosomal abnormality, ${\beta}$-2 microglobulin, and albumin. Recently, the term chromothripsis has emerged, which is the massive but highly localized chromosomal rearrangement in response to a one-step catastrophic event. Many studies have shown an association of chromothripsis with the prognosis in several cancers; however, few studies have investigated it in MM. Here, we studied the association between chromothripsis-like patterns and treatment resistance or prognosis. First, we analyzed nine MM cell lines (U266, MM.1S, RPMI8226, KMS-11, KMS-12-BM, KMS-12-PE, KMS-28-BM, KMS-28-PE, and NCI-H929) and bone marrow samples of four patients who were diagnosed with MM by next-generation sequencing-based copy number variation analysis. The frequency of the chromothripsis-like pattern was observed in seven cell lines. We analyzed the treatment-induced chromothripsis-like patterns in KMS-12-BM and KMS-12-PE cells. As a result, breakpoints and chromothripsis-like patterns were increased after drug treatment in the relatively resistant KMS-12-BM. We further analyzed the patients' results according to the therapeutic response, which was divided into sensitive and resistant, as suggested by the International Myeloma Working Group. The chromothripsis-like pattern was more frequently observed in the resistant group. In the sensitive group, the frequency of the chromothripsis-like pattern decreased after treatment, whereas the resistant group showed increased chromothripsis-like patterns after the treatment. These results suggest that the chromothripsis-like pattern is associated with treatment response in MM.

Keywords

References

  1. Caltagirone S, Ruggeri M, Aschero S, Gilestro M, Oddolo D, Gay F, et al. Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. Haematologica 2014;99:1611-1617. https://doi.org/10.3324/haematol.2014.103853
  2. Ministry of Health and Welfare, Korea Central Cancer Registry, National Cancer Center. Annual report of cancer statistics in Korea in 2014. Goyang: National Cancer Center, 2016. Accessed 2017 Sep 1. Available from: http://ncc.re.kr/cancerStatsView.ncc?bbsnum=417&searchKey=total&searchValue=&pageNum=1.
  3. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-1060. https://doi.org/10.1056/NEJMra1011442
  4. Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012;87:78-88. https://doi.org/10.1002/ajh.22237
  5. Kumar SK, Rajkumar SV. The current status of minimal residual disease assessment in myeloma. Leukemia 2014;28:239-240. https://doi.org/10.1038/leu.2013.306
  6. Hu X, Xuan H, Du H, Jiang H, Huang J. Down-regulation of CD9 by methylation decreased bortezomib sensitivity in multiple myeloma. PLoS One 2014;9:e95765. https://doi.org/10.1371/journal.pone.0095765
  7. Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, et al. NCCN guidelines insights: multiple myeloma, version 3.2016. J Natl Compr Canc Netw 2016;14:389-400. https://doi.org/10.6004/jnccn.2016.0046
  8. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210-2221. https://doi.org/10.1038/leu.2009.174
  9. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011;117:4696-4700. https://doi.org/10.1182/blood-2010-10-300970
  10. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005;23:6333-6338. https://doi.org/10.1200/JCO.2005.05.021
  11. Weissbach S, Langer C, Puppe B, Nedeva T, Bach E, Kull M, et al. The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma. Br J Haematol 2015;169:57-70. https://doi.org/10.1111/bjh.13256
  12. Lim JH, Seo EJ, Park CJ, Jang S, Chi HS, Suh C, et al. Cytogenetic classification in Korean multiple myeloma patients:prognostic significance of hyperdiploidy with 47-50 chromosomes and the number of structural abnormalities. Eur J Haematol 2014;92:313-320. https://doi.org/10.1111/ejh.12257
  13. Morishita M, Muramatsu T, Suto Y, Hirai M, Konishi T, Hayashi S, et al. Chromothripsis-like chromosomal rearrangements induced by ionizing radiation using proton microbeam irradiation system. Oncotarget 2016;7:10182-10192.
  14. Rausch T, Jones DT, Zapatka M, Stutz AM, Zichner T, Weischenfeldt J, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012;148:59-71. https://doi.org/10.1016/j.cell.2011.12.013
  15. Maher CA, Wilson RK. Chromothripsis and human disease: piecing together the shattering process. Cell 2012;148:29-32. https://doi.org/10.1016/j.cell.2012.01.006
  16. Furgason JM, Koncar RF, Michelhaugh SK, Sarkar FH, Mittal S, Sloan AE, et al. Whole genome sequence analysis links chromothripsis to EGFR, MDM2, MDM4, and CDK4 amplification in glioblastoma. Oncoscience 2015;2:618-628. https://doi.org/10.18632/oncoscience.178
  17. Forment JV, Kaidi A, Jackson SP. Chromothripsis and cancer:causes and consequences of chromosome shattering. Nat Rev Cancer 2012;12:663-670. https://doi.org/10.1038/nrc3352
  18. Korbel JO, Campbell PJ. Criteria for inference of chromothripsis in cancer genomes. Cell 2013;152:1226-1236. https://doi.org/10.1016/j.cell.2013.02.023
  19. McDermott DH, Gao JL, Liu Q, Siwicki M, Martens C, Jacobs P, et al. Chromothriptic cure of WHIM syndrome. Cell 2015;160:686-699. https://doi.org/10.1016/j.cell.2015.01.014
  20. Hirsch D, Kemmerling R, Davis S, Camps J, Meltzer PS, Ried T, et al. Chromothripsis and focal copy number alterations determine poor outcome in malignant melanoma. Cancer Res 2013;73:1454-1460. https://doi.org/10.1158/0008-5472.CAN-12-0928
  21. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012;483:589-593. https://doi.org/10.1038/nature10910
  22. Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S. Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. Blood 2011;118:675-678. https://doi.org/10.1182/blood-2011-03-344069
  23. Bao HY, Wang LJ, Yang Y, Cai Z. TLR4 signals are involved in multiple myeloma cell proliferation and apoptosis. Zhejiang Da Xue Xue Bao Yi Xue Ban 2009;38:465-469.
  24. Bolzoni M, Donofrio G, Storti P, Guasco D, Toscani D, Lazzaretti M, et al. Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells. Leukemia 2013;27:451-463. https://doi.org/10.1038/leu.2012.190
  25. Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood 2005;106:698-705. https://doi.org/10.1182/blood-2004-11-4286
  26. Mannava S, Zhuang D, Nair JR, Bansal R, Wawrzyniak JA, Zucker SN, et al. KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. Blood 2012;119:1450-1458. https://doi.org/10.1182/blood-2011-04-346676
  27. Shi Y, Frost P, Hoang B, Benavides A, Gera J, Lichtenstein A. IL-6-induced enhancement of c-Myc translation in multiple myeloma cells: critical role of cytoplasmic localization of the rna-binding protein hnRNP A1. J Biol Chem 2011;286:67-78. https://doi.org/10.1074/jbc.M110.153221
  28. Silvestris F, Cafforio P, De Matteo M, Calvani N, Frassanito MA, Dammacco F. Negative regulation of the osteoblast function in multiple myeloma through the repressor gene E4BP4 activated by malignant plasma cells. Clin Cancer Res 2008;14:6081-6091. https://doi.org/10.1158/1078-0432.CCR-08-0219
  29. Tam M, Lin P, Hu P, Lennon PA. Examining Hedgehog pathway genes GLI3, SHH, and PTCH1 and the p53 target GLIPR1/GLIPR1L1/GLIPR1L2 gene cluster using fluorescence in situ hybridization uncovers GLIPR1/GLIPR1L1/GLIPR1L2 deletion in 9% of patients with multiple myeloma. J Assoc Genet Technol 2010;36:111-114.
  30. Yu T, Liu L, Zhang S, Hao M, Qiu L. PHF19 promotes drug resistance through EZH2 inactivation in multiple myeloma. Blood 2016;128:4495.
  31. Yang Y, Zhou W, Xia J, Gu Z, Wendlandt E, Zhan X, et al. NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma. Oncotarget 2014;5:11986-11997.
  32. Brigaudeau C, Trimoreau F, Gachard N, Rouzier E, Jaccard A, Bordessoule D, et al. Cytogenetic study of 30 patients with multiple myeloma: comparison of 3 and 6 day bone marrow cultures stimulated or not with cytokines by using a miniaturized karyotypic method. Br J Haematol 1997;96:594-600. https://doi.org/10.1046/j.1365-2141.1997.d01-2073.x
  33. Fabris S, Ronchetti D, Agnelli L, Baldini L, Morabito F, Bicciato S, et al. Transcriptional features of multiple myeloma patients with chromosome 1q gain. Leukemia 2007;21:1113-1116. https://doi.org/10.1038/sj.leu.2404616
  34. Inoue J, Otsuki T, Hirasawa A, Imoto I, Matsuo Y, Shimizu S, et al. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am J Pathol 2004;165:71-81. https://doi.org/10.1016/S0002-9440(10)63276-2
  35. Mani M, Carrasco DE, Zhang Y, Takada K, Gatt ME, Dutta-Simmons J, et al. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res 2009;69:7577-7586. https://doi.org/10.1158/0008-5472.CAN-09-0773
  36. Yasmeen R, Meyers JM, Alvarez CE, Thomas JL, Bonnegarde-Bernard A, Alder H, et al. Aldehyde dehydrogenase-1a1 induces oncogene suppressor genes in B cell populations. Biochim Biophys Acta 2013;1833:3218-3227. https://doi.org/10.1016/j.bbamcr.2013.09.012
  37. Shaughnessy JD Jr, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood 2011;118:3512-3524. https://doi.org/10.1182/blood-2010-12-328252
  38. Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 2010;116:e56-e65. https://doi.org/10.1182/blood-2010-04-279596
  39. Xu X, He Y, Miao X, Wu Y, Han J, Wang Q, et al. Cell adhesion induces overexpression of chromodomain helicase/ATPase DNA binding protein 1-like gene (CHD1L) and contributes to cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma cells. Leuk Res 2016;47:54-62. https://doi.org/10.1016/j.leukres.2016.05.007
  40. Dvorakova K, Payne CM, Tome ME, Briehl MM, Vasquez MA, Waltmire CN, et al. Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells. Mol Cancer Ther 2002;1:185-195.
  41. Pan YZ, Wang X, Bai H, Wang CB, Zhang Q, Xi R. Autophagy in drug resistance of the multiple myeloma cell line RPMI8226 to doxorubicin. Genet Mol Res 2015;14:5621-5629. https://doi.org/10.4238/2015.May.25.14
  42. Friday E, Ledet J, Turturro F. Response to dexamethasone is glucose-sensitive in multiple myeloma cell lines. J Exp Clin Cancer Res 2011;30:81. https://doi.org/10.1186/1756-9966-30-81
  43. Munshi NC, Anderson KC. Advances in Biology and Therapy of Multiple Myeloma. Vol. 1. Basic Science. New York: Springer-Verlag, 2013.
  44. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012;12:335-348. https://doi.org/10.1038/nrc3257
  45. Stevens-Kroef M, Weghuis DO, Croockewit S, Derksen L, Hooijer J, Elidrissi-Zaynoun N, et al. High detection rate of clinically relevant genomic abnormalities in plasma cells enriched from patients with multiple myeloma. Genes Chromosomes Cancer 2012;51:997-1006. https://doi.org/10.1002/gcc.21982